Aspirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG)
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Incidence of More Than 50% Stenosis in Graft With Combination Therapy With Aspirin and Clopidogrel vs. Aspirin Alone
研究概览
简要总结
The design of the study will be randomized, double blind trial, which will examine the effects of addition of clopidogrel to current guideline recommended background therapy on lowering the incidence of graft stenosis after coronary artery bypass grafting compared to placebo.
详细描述
The purpose of this study is to evaluate how well the combination of clopidogrel and aspirin lower the risk of clot forming in the bypass graft after open heart surgery. This combination has not yet been approved by the Food & Drug Administration (FDA) for treating clots in the bypass graft. However, the FDA has not objected to its use to study its safety and effectiveness. This study will enroll approximately 150 total subjects all of which will be at Brooke Army Medical Center/Wilford Hall Medical Center. The study will be for 52 weeks from the day of surgery.
After bypass surgery and inclusion criteria is met, subjects will be placed on aspirin 81 mg once daily and placebo once daily or aspirin 81 mg once daily and clopidogrel 75mg once daily to keep the bypass grafts open after surgery. There are no studies to date comparing the two study groups A CT scan of the heart will be done 2 weeks after surgery to see if the grafts are still open. At the end of the study, at 52-weeks mark, the subjects will undergo another heart scan to evaluate the bypass grafts and see if they are still open.
Subjects will be seen on a 3 months basis until the end of the study, unless deemed necessary to return earlier for follow up. Subjects will undergo blood draw for complete blood count as part of the follow up visits to assess for safety while on the current study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients undergoing coronary artery bypass grafting, with or without cardiopulmonary bypass
排除标准
- •Left ventricle ejection fraction <30%
- •Emergency surgery
- •Valve surgery
- •Redo CABG
- •Postoperative cardiogenic shock for more than 48 hours
- •Postoperative bleeding or cardiac tamponade
- •More than 24 hours postoperative intubation course
- •Requirement of postoperative anticoagulation
- •Serum creatinine >1.4
- •Contraindication to use of postoperative coronary CT scan
- •Allergy or contraindication to aspirin or clopidogrel
- •Inability to provide informed consent
- •Pregnant or breast feeding females
研究组 & 干预措施
clopidogrel
aspirin and clopidogrel
干预措施: clopidogrel (Drug)
clopidogrel
aspirin and clopidogrel
干预措施: Aspirin (Drug)
sugar pill
aspirin and placebo
干预措施: sugar pill (Drug)
sugar pill
aspirin and placebo
干预措施: Aspirin (Drug)
结局指标
主要结局
Incidence of More Than 50% Stenosis in Graft With Combination Therapy With Aspirin and Clopidogrel vs. Aspirin Alone
时间窗: 52 weeks
Incidence of more than 50% stenosis in graft with combination therapy with aspirin and clopidogrel vs. aspirin and placebo
次要结局
- Incidence of Bleeding Between the Two Treatment Arms(52 weeks)
- Number of Thrombotic Events(52 weeks)
- Number of Myocardial Infarction Events(52 weeks)
- Number of Angina Events(52 weeks)
- Number of Major Adverse Cardiovascular Events With Combination Therapy(52 weeks)
研究者
Ahmad Slim
director, cardiovascular research
Brooke Army Medical Center